Pancreatic cancer, hematologic cancers, lung cancer, stomach cancer, and brain cancer pose the highest risk of recurrent VTE for cancer patients experiencing pulmonary embolism, making prolonged anticoagulation essential, with a preference for LMWH or DOACs over VKAs.